Bank of New York Mellon Corp Makes New Investment in United Therapeutics Corporation $UTHR

Bank of New York Mellon Corp acquired a new position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 294,413 shares of the biotechnology company's stock, valued at approximately $159,522,000. Bank of New York Mellon Corp owned about 0.69% of United Therapeutics at the end of the most recent quarter.

Several other large investors have also modified their holdings of UTHR. Arjuna Capital lifted its position in shares of United Therapeutics by 2.8% during the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock worth $393,000 after purchasing an additional 18 shares during the last quarter. Sage Rhino Capital LLC lifted its holdings in shares of United Therapeutics by 5.1% during the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock worth $281,000 after buying an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC lifted its holdings in shares of United Therapeutics by 5.4% during the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock worth $276,000 after buying an additional 24 shares during the last quarter. Meeder Advisory Services Inc. boosted its position in shares of United Therapeutics by 4.1% in the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company's stock valued at $392,000 after acquiring an additional 26 shares during the period. Finally, Independent Advisor Alliance boosted its position in shares of United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company's stock valued at $406,000 after acquiring an additional 27 shares during the period. 94.08% of the stock is owned by institutional investors.

United Therapeutics Stock Performance

UTHR stock opened at $513.12 on Monday. United Therapeutics Corporation has a 1-year low of $302.19 and a 1-year high of $609.35. The business's 50 day moving average is $533.08 and its 200-day moving average is $537.80. The firm has a market cap of $22.01 billion, a P/E ratio of 18.36, a P/E/G ratio of 1.74 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the previous year, the firm earned $6.41 EPS. United Therapeutics's quarterly revenue was down 1.9% on a year-over-year basis. Sell-side analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on UTHR. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research report on Thursday, August 6th. Wells Fargo & Company raised United Therapeutics from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Weiss Ratings upgraded United Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research report on Thursday, August 13th. Royal Bank Of Canada decreased their price objective on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. boosted their price objective on United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research report on Thursday, July 23rd. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $646.00.

Insider Transactions at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $546.28, for a total value of $5,462,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,311,581.28. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business's stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $547.62, for a total value of $5,202,390.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at $22,185,729.06. The trade was a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 442,575 shares of company stock worth $239,326,330. Company insiders own 8.60% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source